CY1111869T1 - PHARMACEUTICAL COMPOSITIONS AND METHODS USED FOR TREATMENT OF CANCER OR US FIBOS - Google Patents

PHARMACEUTICAL COMPOSITIONS AND METHODS USED FOR TREATMENT OF CANCER OR US FIBOS

Info

Publication number
CY1111869T1
CY1111869T1 CY20111100336T CY111100336T CY1111869T1 CY 1111869 T1 CY1111869 T1 CY 1111869T1 CY 20111100336 T CY20111100336 T CY 20111100336T CY 111100336 T CY111100336 T CY 111100336T CY 1111869 T1 CY1111869 T1 CY 1111869T1
Authority
CY
Cyprus
Prior art keywords
fibos
cancer
treatment
pharmaceutical compositions
methods used
Prior art date
Application number
CY20111100336T
Other languages
Greek (el)
Inventor
Gera Neufeld
Gal Akiri
Zahava Vadasz
Stela Gengrovitch
Original Assignee
Technion Research And Development Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technion Research And Development Foundation Ltd filed Critical Technion Research And Development Foundation Ltd
Publication of CY1111869T1 publication Critical patent/CY1111869T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
    • C12Y104/03—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • C12Y104/03013—Protein-lysine 6-oxidase (1.4.3.13), i.e. lysyl-oxidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
    • C12N9/0022—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A method of modulating angiogenesis in a mammalian tissue is provided. The method including administering into the mammalian tissue a molecule capable of modifying a tissue level and/or activity of at least one type of lysyl-oxidase to thereby modulate angiogenesis in the mammalian tissue.
CY20111100336T 2000-08-08 2011-03-29 PHARMACEUTICAL COMPOSITIONS AND METHODS USED FOR TREATMENT OF CANCER OR US FIBOS CY1111869T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22373900P 2000-08-08 2000-08-08
EP01958338A EP1315519B1 (en) 2000-08-08 2001-08-07 Pharmaceutical compositions and methods useful for treating cancer or liver fibrosis

Publications (1)

Publication Number Publication Date
CY1111869T1 true CY1111869T1 (en) 2015-11-04

Family

ID=22837793

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20111100336T CY1111869T1 (en) 2000-08-08 2011-03-29 PHARMACEUTICAL COMPOSITIONS AND METHODS USED FOR TREATMENT OF CANCER OR US FIBOS
CY20121100746T CY1113142T1 (en) 2000-08-08 2012-08-21 PHARMACEUTICAL COMPOSITIONS AND METHODS USED FOR CONSTRUCTION OF VASCULATION
CY20131101162T CY1114734T1 (en) 2000-08-08 2013-12-23 PHARMACEUTICAL COMPOSITIONS AND METHODS USED FOR VASCULAR ADJUSTMENT

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY20121100746T CY1113142T1 (en) 2000-08-08 2012-08-21 PHARMACEUTICAL COMPOSITIONS AND METHODS USED FOR CONSTRUCTION OF VASCULATION
CY20131101162T CY1114734T1 (en) 2000-08-08 2013-12-23 PHARMACEUTICAL COMPOSITIONS AND METHODS USED FOR VASCULAR ADJUSTMENT

Country Status (10)

Country Link
EP (4) EP1315519B1 (en)
AT (1) ATE493147T1 (en)
AU (1) AU2001280056A1 (en)
CY (3) CY1111869T1 (en)
DE (1) DE60143754D1 (en)
DK (4) DK2359853T3 (en)
ES (4) ES2387329T3 (en)
HK (3) HK1161113A1 (en)
PT (4) PT2078531E (en)
WO (1) WO2002011667A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114410A1 (en) * 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
US20030224989A1 (en) * 2002-02-12 2003-12-04 Kerry Quinn Compositions and methods for treatment of osteoarthritis
FR2855968B1 (en) 2003-06-13 2012-11-30 Coletica STIMULATION OF THE SYNTHESIS AND ACTIVITY OF A LYSYL OXIDASE-LIKE LOXL ISOFORM TO STIMULATE THE FORMATION OF ELASTIC FIBERS
US7255856B2 (en) 2004-01-23 2007-08-14 Massachusetts Eye & Ear Infirmary Lysyl oxidase-like 1 (LOXL1) and elastogenesis
WO2006128740A2 (en) * 2005-06-02 2006-12-07 Centelion Anti-vascular methods and therapies employing lysyl oxidase inhibitors
IL184627A0 (en) 2007-07-15 2008-12-29 Technion Res & Dev Foundation Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue
ES2402334T3 (en) 2007-08-02 2013-04-30 Gilead Biologics, Inc Procedures and compositions for the treatment and diagnosis of fibrosis
DE102007051006A1 (en) * 2007-10-25 2009-04-30 Lanxess Deutschland Gmbh Stable, synergistic mixtures
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
AU2010284036B2 (en) 2009-08-21 2014-12-18 Gilead Biologics, Inc. Catalytic domains from lysyl oxidase and LOXL2
MX2012009088A (en) 2010-02-04 2012-12-05 Gilead Biologics Inc Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor.

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (en) 1971-02-10 1977-09-15 Organon Nv METHOD FOR THE DETERMINATION AND DETERMINATION OF SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES.
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
NL154599B (en) 1970-12-28 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES, AND TEST PACKAGING.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (en) 1972-05-11 1983-06-01 Akzo Nv METHOD FOR DETERMINING AND DETERMINING BITES AND TEST PACKAGING.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5021404A (en) * 1988-04-20 1991-06-04 The Children's Medical Center Corporation Angiostatic collagen modulators
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
DK51092D0 (en) 1991-05-24 1992-04-15 Ole Buchardt OLIGONUCLEOTIDE ANALOGUE DESCRIBED BY PEN, MONOMERIC SYNTHONES AND PROCEDURES FOR PREPARING THEREOF, AND APPLICATIONS THEREOF
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US6300092B1 (en) * 1999-01-27 2001-10-09 Millennium Pharmaceuticals Inc. Methods of use of a novel lysyl oxidase-related protein
WO2001083702A2 (en) * 2000-05-03 2001-11-08 University Of Hawaii Novel members of the lysyl oxidases family of amine oxidases related applications
US20030114410A1 (en) * 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis

Also Published As

Publication number Publication date
HK1161113A1 (en) 2012-08-24
HK1161115A1 (en) 2012-08-24
DK1315519T3 (en) 2011-04-11
EP2359853B1 (en) 2013-11-06
EP2359854A1 (en) 2011-08-24
PT1315519E (en) 2011-03-17
EP1315519A4 (en) 2005-09-14
EP2359853A1 (en) 2011-08-24
EP2078531B1 (en) 2012-05-30
WO2002011667A2 (en) 2002-02-14
ATE493147T1 (en) 2011-01-15
CY1113142T1 (en) 2016-04-13
ES2440932T3 (en) 2014-01-31
DK2359854T3 (en) 2013-11-04
DE60143754D1 (en) 2011-02-10
ES2437093T3 (en) 2014-01-08
DK2078531T3 (en) 2012-09-10
PT2359854E (en) 2013-11-22
EP1315519A2 (en) 2003-06-04
CY1114734T1 (en) 2016-12-14
EP2078531A2 (en) 2009-07-15
DK2359853T3 (en) 2013-12-09
ES2358581T3 (en) 2011-05-12
ES2387329T3 (en) 2012-09-20
EP2359854B1 (en) 2013-10-09
PT2078531E (en) 2012-08-06
EP2078531A3 (en) 2010-01-20
PT2359853E (en) 2013-12-26
AU2001280056A1 (en) 2002-02-18
HK1131912A1 (en) 2010-02-12
EP1315519B1 (en) 2010-12-29
WO2002011667A3 (en) 2003-03-27

Similar Documents

Publication Publication Date Title
CY1111869T1 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS USED FOR TREATMENT OF CANCER OR US FIBOS
BR9807816A (en) Laser-assisted topical anesthetic permeation
ATE319447T1 (en) PHARMACEUTICAL PREPARATIONS CONTAINING CLAVULANIC ACID OR DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
DE69215722D1 (en) Amplifiers for the ultrasound therapy of diseases and liquid pharmaceutical compositions containing them
ATE340581T1 (en) METHOD FOR TREATING PROSTATE DISEASES USING DELAYED AND/OR EXTENDED RELEASE VITAMIN D FORMULATIONS
PT1165044E (en) HIGH POWER DI-HYDRO-PYROTAMINE COMPOUNDS
ATE482227T1 (en) MODULATORS OF PHARMACOLOGICAL AGENTS
ATE383167T1 (en) COMPOSITIONS CONTAINING DNA DESTRUCTIVE AGENTS AND P53
DE69731652D1 (en) METHOD FOR TREATING ENDOTHELIAL INJURIES
ATA91797A (en) A PHARMACEUTICAL PREPARATION CONTAINING THE VWF PROPEPTIDE
BR9813318A (en) Process of treating tumors and macular degeneration in a human or veterinary patient, pharmaceutical composition for treating tumors and macular degeneration in a human or veterinary patient
ATE231388T1 (en) LONG-ACTING AGENT FOR RECTAL ADMINISTRATION
DE69108748D1 (en) Antithrombin solution and its use.
ATE428438T1 (en) MEDICAL COMPOSITION CONTAINING TCF-II
ATE5256T1 (en) PHENYLPIPERAZIN DERIVATIVES OF 1,3,4OXADIAZOLYLPENOLS, THEIR PREPARATION AND THERAPEUTIC AGENTS CONTAINING THEM.
ATE185274T1 (en) THERAPEUTIC AGENT AGAINST RISK OF ABORTION
ATE106732T1 (en) MEDICATION PREPARATION CONTAINING STIGMASTA-4-EN-3-ONE AND USE THEREOF.
ATE56147T1 (en) MEDICINAL PREPARATION CONTAINING T-PA AND USE THEREOF.
ES2077698T3 (en) THERAPEUTIC AGENT FOR THE DIABETIC GANGRENA.
CY1114741T1 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS USED IN CONSTRUCTION OF VASCULATION